MDK74978

• CAT Number: I007933
• CAS Number: 778274-97-8
• Molecular Formula: C20H17F3N4O3
• Molecular Weight: 418.376
• Purity: ≥95%
• Synonyms: MDK74978; MDK-74978; MDK 74978. Multi-kinase inhibitor I;N-(2-Hydroxyethyl)-4-[6-[4-(trifluoromethoxy)anilino]pyrimidin-4-yl]benzamide
• Target: PDGFR
• Solubility: Soluble in DMSO
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• IUPAC Name: N-(2-hydroxyethyl)-4-[6-[4-(trifluoromethoxy)anilino]pyrimidin-4-yl]benzamide
• InChI: InChI=1S/C20H17F3N4O3/c21-20(22,23)30-16-7-5-15(6-8-16)27-18-11-17(25-12-26-18)13-1-3-14(4-2-13)19(29)24-9-10-28/h1-8,11-12,28H,9-10H2,(H,24,29)(H,25,26,27)
• InChIKey: DEGDCVFNFAOIPU-UHFFFAOYSA-N
• SMILES: C1=CC(=CC=C1C2=CC(=NC=N2)NC3=CC=C(C=C3)OC(F)(F)F)C(=O)NCCO

MDK74978(CAT: I007933), also known as Multi-kinase inhibitor I, is a compound categorized as a multi-kinase inhibitor. As a multi-kinase inhibitor, it exhibits the ability to simultaneously target and inhibit the activity of multiple kinases, which are enzymes involved in cellular signaling pathways. By inhibiting multiple kinases, MDK74978 can interfere with various signaling cascades, potentially affecting cellular processes such as proliferation, angiogenesis, and survival. The broad inhibitory profile of MDK74978 against multiple kinases makes it a valuable tool in cancer research and drug discovery, where dysregulated kinase signaling is often implicated in tumorigenesis and disease progression.

Reference

1: Chang Hsu Y, Selvaraj Coumar M, Wang WC, Shiao HY, Ke YY, Lin WH, Kuo CC, Chang CW, Kuo FM, Chen PY, Wang SY, Li AS, Chen CH, Kuo PC, Chen CP, Wu MH, Huang CL, Yen KJ, Chang YI, Hsu JT, Chen CT, Yeh TK, Song JS, Shih C, Hsieh HP. Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation. Oncotarget. 2016 Nov 15. doi: 10.18632/oncotarget.13369. [Epub ahead of print] PubMed PMID: 27863392.2:García-Vilas JA, Pino-Ángeles A, Martínez-Poveda B, Quesada AR, Medina MÁ. The noni anthraquinone damnacanthal is a multi-kinase inhibitor with potent anti-angiogenic effects. Cancer Lett. 2017 Jan 28;385:1-11. doi: 10.1016/j.canlet.2016.10.037. PubMed PMID: 27816491.